Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Head and Neck Cancer

  Free Subscription

Articles published in Clin Cancer Res

Retrieve available abstracts of 85 articles:
HTML format

Single Articles

    December 2022
  1. AGGARWAL C, Saba NF, Algazi A, Sukari A, et al
    Safety and Efficacy of MEDI0457 Plus Durvalumab in Patients With Human Papillomavirus-associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2022 Dec 1:CCR-22-1987. doi: 10.1158/1078-0432.CCR-22-1987.
    PubMed     Abstract available

    November 2022
  2. RODRIGUEZ-RAMIREZ C, Zhang Z, Warner KA, Herzog AE, et al
    p53 Inhibits Bmi-1-driven Self-Renewal and Defines Salivary Gland Cancer Stemness.
    Clin Cancer Res. 2022;28:4757-4770.
    PubMed     Abstract available

  3. FERGUSON AL, Sharman AR, Allen RO, Ye T, et al
    High-Dimensional and Spatial Analysis Reveals Immune Landscape-Dependent Progression in Cutaneous Squamous Cell Carcinoma.
    Clin Cancer Res. 2022;28:4677-4688.
    PubMed     Abstract available

    October 2022
  4. CABANILLAS ME, Busaidy NL, Sherman SI
    Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.
    Clin Cancer Res. 2022;28:4164-4166.
    PubMed     Abstract available

    HPV DNA as a Biomarker in Oropharyngeal Cancer: A Step in the Right Direction.
    Clin Cancer Res. 2022;28:4171-4172.
    PubMed     Abstract available

  6. BERGER BM, Hanna GJ, Posner MR, Genden EM, et al
    Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma.
    Clin Cancer Res. 2022;28:4292-4301.
    PubMed     Abstract available

    September 2022
  7. PAUDEL S, Warner BE, Wang R, Adams-Haduch J, et al
    Serological profiling using an Epstein-Barr virus mammalian expression library identifies EBNA1 IgA as a pre-diagnostic marker for nasopharyngeal carcinoma.
    Clin Cancer Res. 2022 Sep 27. pii: 709488. doi: 10.1158/1078-0432.CCR-22-1600.
    PubMed     Abstract available

  8. MIERZWA ML, Aryal M, Lee C, Schipper M, et al
    Randomized Phase II study of Physiologic MRI-directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer.
    Clin Cancer Res. 2022 Sep 15. pii: 709219. doi: 10.1158/1078-0432.CCR-22-1522.
    PubMed     Abstract available

  9. YU M, Moinova HR, Willbanks A, Cannon VK, et al
    Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia.
    Clin Cancer Res. 2022;28:3761-3769.
    PubMed     Abstract available

  10. ROHRER BLEY C, Wolf F, Goncalves Jorge P, Grilj V, et al
    Dose- and Volume-Limiting Late Toxicity of FLASH Radiotherapy in Cats with Squamous Cell Carcinoma of the Nasal Planum and in Mini Pigs.
    Clin Cancer Res. 2022;28:3814-3823.
    PubMed     Abstract available

    August 2022
  11. QURESHY Z, Li H, Zeng Y, Rivera J, et al
    STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer.
    Clin Cancer Res. 2022 Aug 5. pii: 707467. doi: 10.1158/1078-0432.CCR-22-0744.
    PubMed     Abstract available

  12. LEE YJ, van den Berg NS, Duan H, Azevedo EC, et al
    89Zr-panitumumab combined with 18F-FDG-PET improves detection and staging of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2022 Aug 5. pii: 707464. doi: 10.1158/1078-0432.CCR-22-0094.
    PubMed     Abstract available

  13. YOON HH, Dong H, Shi Q
    Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.
    Clin Cancer Res. 2022;28:3173-3175.
    PubMed     Abstract available

  14. HONG X, Li Q, Li J, Chen K, et al
    CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization.
    Clin Cancer Res. 2022 Aug 2. pii: 707414. doi: 10.1158/1078-0432.CCR-22-0991.
    PubMed     Abstract available

    July 2022
  15. ZHU M, Chen C, Foster NR, Hartley C, et al
    Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction.
    Clin Cancer Res. 2022;28:3021-3031.
    PubMed     Abstract available

  16. JUNG HA, Park KU, Cho S, Lim J, et al
    A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
    Clin Cancer Res. 2022 Jul 12. pii: 706988. doi: 10.1158/1078-0432.CCR-22-1238.
    PubMed     Abstract available

  17. SCHMITD LB, Perez-Pacheco C, Bellile EL, Wu W, et al
    Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer.
    Clin Cancer Res. 2022 Jul 12:OF1-OF16. doi: 10.1158/1078-0432.CCR-21-4543.
    PubMed     Abstract available

  18. LYNGGAARD CD, Gronhoj C, Jensen SB, Christensen R, et al
    Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial.
    Clin Cancer Res. 2022;28:2890-2897.
    PubMed     Abstract available

    June 2022
  19. ZHANG Z, Wu B, Peng G, Xiao G, et al
    Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.
    Clin Cancer Res. 2022 Jun 29:OF1-OF9. doi: 10.1158/1078-0432.CCR-22-0666.
    PubMed     Abstract available

  20. SIHAG S, Nussenzweig SC, Walch HS, Hsu M, et al
    The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma.
    Clin Cancer Res. 2022;28:2669-2678.
    PubMed     Abstract available

  21. DUKE ES, Barone AK, Chatterjee S, Mishra-Kalyani PS, et al
    FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
    Clin Cancer Res. 2022 Jun 9. pii: 704846. doi: 10.1158/1078-0432.CCR-22-0873.
    PubMed     Abstract available

  22. LEE KW, Van Cutsem E, Bang YJ, Fuchs CS, et al
    Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
    Clin Cancer Res. 2022 Jun 3. pii: 699374. doi: 10.1158/1078-0432.CCR-22-0121.
    PubMed     Abstract available

  23. LEDDON JL, Gulati S, Haque S, Allen C, et al
    Phase 2 trial of adjuvant nivolumab following salvage resection in patients with recurrent squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2022 Jun 2. pii: 699312. doi: 10.1158/1078-0432.CCR-21-4554.
    PubMed     Abstract available

    May 2022
  24. WANG W, Lozar T, Golfinos AE, Lee D, et al
    Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade.
    Clin Cancer Res. 2022 May 27:OF1-OF16. doi: 10.1158/1078-0432.CCR-21-3039.
    PubMed     Abstract available

  25. SCHMITD LB, Perez-Pacheco C, Bellile EL, Wu W, et al
    Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer.
    Clin Cancer Res. 2022 May 26. pii: 699248. doi: 10.1158/1078-0432.CCR-21-4543.
    PubMed     Abstract available

  26. WEBER M, Kersting D, Riemann B, Brandenburg T, et al
    Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancer With MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
    Clin Cancer Res. 2022 May 20. pii: 699089. doi: 10.1158/1078-0432.CCR-22-0437.
    PubMed     Abstract available

  27. DENEKA AY, Baca Y, Serebriiskii IG, Nicolas E, et al
    Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
    Clin Cancer Res. 2022;28:1925-1937.
    PubMed     Abstract available

    April 2022
  28. LE X, Gleber-Netto FO, Rubin ML, Qing Y, et al
    Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection.
    Clin Cancer Res. 2022 Apr 20. pii: 694632. doi: 10.1158/1078-0432.CCR-21-3239.
    PubMed     Abstract available

  29. FERRAROTTO R, Amit M, Nagarajan P, Rubin ML, et al
    Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Clin Cancer Res. 2022;28:1735.

  30. LEE AW, Ng WT, Choi CW, But B, et al
    Exploratory Study of NPC-0501 Trial - Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2022 Apr 5. pii: 694221. doi: 10.1158/1078-0432.CCR-21-3375.
    PubMed     Abstract available

  31. GUIX I, Liu Q, Pujana MA, Ha P, et al
    Validation of Anticorrelated TGFbeta Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy.
    Clin Cancer Res. 2022;28:1372-1382.
    PubMed     Abstract available

    March 2022
  32. CHUNG CH, Li J, Steuer CE, Bhateja P, et al
    Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma.
    Clin Cancer Res. 2022 Mar 28. pii: 694028. doi: 10.1158/1078-0432.CCR-21-3849.
    PubMed     Abstract available

  33. OKADA M, Kato K, Cho BC, Takahashi M, et al
    Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3).
    Clin Cancer Res. 2022 Mar 16. pii: 682194. doi: 10.1158/1078-0432.CCR-21-0985.
    PubMed     Abstract available

  34. RICKELT S, Neyaz A, Condon C, Whittaker CA, et al
    Agrin Loss in Barrett's Esophagus-Related Neoplasia and Its Utility as a Diagnostic and Predictive Biomarker.
    Clin Cancer Res. 2022;28:1167-1179.
    PubMed     Abstract available

  35. OBRADOVIC A, Graves D, Korrer M, Wang Y, et al
    Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer.
    Clin Cancer Res. 2022 Mar 9. pii: 682113. doi: 10.1158/1078-0432.CCR-21-3570.
    PubMed     Abstract available

    February 2022
  36. WISE-DRAPER TM, Gulati S, Palackdharry S, Hinrichs BH, et al
    Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2022 Feb 28:OF1-OF8. doi: 10.1158/1078-0432.CCR-21-3351.
    PubMed     Abstract available

  37. XU Y, Dong B, Zhu W, Li J, et al
    A phase III multicenter randomized clinical trial of 60 Gy vs 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma.
    Clin Cancer Res. 2022 Feb 18. pii: 681705. doi: 10.1158/1078-0432.CCR-21-3843.
    PubMed     Abstract available

  38. SACCO AG, Cohen EEW
    Inevitable Progress-Relying on the Immune System, Not Chance.
    Clin Cancer Res. 2022;28:435-437.
    PubMed     Abstract available

    January 2022
  39. FERRIS RL, Moskovitz J, Kunning S, Ruffin AT, et al
    Phase I trial of cetuximab, radiation therapy, and ipilimumab in locally advanced head and neck cancer.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-0426.
    PubMed     Abstract available

  40. KAO HF, Liao BC, Huang YL, Huang HC, et al
    Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3025.
    PubMed     Abstract available

  41. LI Y, Yang X, Du X, Lei Y, et al
    Correction: RAB37 Hypermethylation Regulates Metastasis and Resistance to Docetaxel-Based Induction Chemotherapy in Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2022;28:430.

  42. CAO Y, Haring CT, Brummel C, Bhambhani C, et al
    Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2022;28:350-359.
    PubMed     Abstract available

    December 2021
  43. WEBER P, Kunstner A, Hess J, Unger K, et al
    Therapy-related transcriptional subtypes in matched primary and recurrent head and neck cancer.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-2244.
    PubMed     Abstract available

  44. COHEN EEW, Nabell L, Wong DJ, Day T, et al
    Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive head and neck squamous cell carcinoma: results from a multicenter, phase 2 trial.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1411.
    PubMed     Abstract available

  45. LUGINBUHL AJ, Johnson JM, Harshyne LA, Linnenbach AJ, et al
    Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma.
    Clin Cancer Res. 2021 Dec 15. pii: 1078-0432.CCR-21-1816.
    PubMed     Abstract available

  46. YAP TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, et al
    First-In-Human Phase I Study of a Next-Generation, Oral, TGFbeta Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.
    Clin Cancer Res. 2021;27:6666-6676.
    PubMed     Abstract available

  47. PANG J, Nguyen N, Luebeck J, Ball L, et al
    Extrachromosomal DNA in HPV-Mediated Oropharyngeal Cancer Drives Diverse Oncogene Transcription.
    Clin Cancer Res. 2021;27:6772-6786.
    PubMed     Abstract available

  48. TAYLOR MH, Betts CB, Maloney L, Nadler E, et al
    Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
    Clin Cancer Res. 2021 Dec 3. pii: 1078-0432.CCR-21-2547.
    PubMed     Abstract available

  49. SIRAVEGNA G, O'Boyle CJ, Varmeh S, Queenan N, et al
    Cell free HPV DNA provides an accurate and rapid diagnosis of HPV-associated head and neck cancer.
    Clin Cancer Res. 2021 Dec 2. pii: 1078-0432.CCR-21-3151.
    PubMed     Abstract available

  50. EVEN C, Wang HM, Li SH, Ngan RK, et al
    Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer.
    Clin Cancer Res. 2021;27:6413-6423.
    PubMed     Abstract available

    November 2021
  51. KATABATHULA R, Joseph P, Singh S, Zhao S, et al
    Multi-scale Pan-cancer Integrative Analyses Identify the STAT3-VSIR Axis as a key Immunosuppressive Mechanism in Head and Neck Cancer.
    Clin Cancer Res. 2021 Nov 16. pii: 1078-0432.CCR-21-1978.
    PubMed     Abstract available

  52. BICKETT TE, Knitz M, Darragh LB, Bhatia S, et al
    FLT3L Release by Natural Killer Cells Enhances Response to Radioimmunotherapy in Preclinical Models of HNSCC.
    Clin Cancer Res. 2021;27:6235-6249.
    PubMed     Abstract available

  53. LEUNG E, Han K, Zou J, Zhao Z, et al
    HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA.
    Clin Cancer Res. 2021;27:5857-5868.
    PubMed     Abstract available

    October 2021
  54. HANNA GJ, ONeill A, Shin KY, Wong K, et al
    Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2635.
    PubMed     Abstract available

    September 2021
  55. ZHANG JX, Chen ZH, Xu Y, Chen JW, et al
    Correction: Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell-like Phenotype via Dysregulation of PITX2.
    Clin Cancer Res. 2021;27:4942.

  56. DE LA IGLESIA JV, Slebos RJC, Martin-Gomez L, Wang X, et al
    Correction: Effects of Tobacco Smoking On the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2021;27:4941.

    August 2021
  57. VYAS A, Harbison RA, Faden DL, Kubik M, et al
    Recurrent human papillomavirus-related head and neck cancer undergoes metabolic re-programming and is driven by oxidative phosphorylation.
    Clin Cancer Res. 2021 Aug 18. pii: 1078-0432.CCR-20-4789.
    PubMed     Abstract available

  58. XIA WX, Lv X, Liang H, Liu GY, et al
    A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer.
    Clin Cancer Res. 2021;27:4186-4194.
    PubMed     Abstract available

    July 2021
  59. ZHENG X, Xu Z, Ji Q, Ge M, et al
    A randomized, phase 3 study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2021 Jul 29. pii: 1078-0432.CCR-21-0761.
    PubMed     Abstract available

  60. BRAND TM, Hartmann S, Bhola NE, Peyser ND, et al
    Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV(+) Patients.
    Clin Cancer Res. 2021;27:4129.

  61. KARPINETS TV, Mitani Y, Liu B, Zhang J, et al
    Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations.
    Clin Cancer Res. 2021;27:3960-3969.
    PubMed     Abstract available

  62. CHENG NM, Yao J, Cai J, Ye X, et al
    Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging.
    Clin Cancer Res. 2021;27:3948-3959.
    PubMed     Abstract available

  63. LABIANO S, Roh V, Godfroid C, Hiou-Feige A, et al
    CD40 Agonist Targeted to Fibroblast Activation Protein alpha Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors.
    Clin Cancer Res. 2021;27:4054-4065.
    PubMed     Abstract available

  64. DE CLERCQ NC, van den Ende T, Prodan A, Hemke R, et al
    Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study.
    Clin Cancer Res. 2021;27:3784-3792.
    PubMed     Abstract available

    June 2021
  65. FERRAROTTO R, Amit M, Nagarajan P, Rubin ML, et al
    Pilot phase II trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Clin Cancer Res. 2021 Jun 29. pii: 1078-0432.CCR-21-0585.
    PubMed     Abstract available

  66. BURGENER JM, Zou J, Zhao Z, Zheng Y, et al
    Tumor-Naive Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2021 Jun 22. pii: 1078-0432.CCR-21-0110.
    PubMed     Abstract available

  67. VAN DEN ENDE T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, et al
    Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
    Clin Cancer Res. 2021;27:3351-3359.
    PubMed     Abstract available

  68. PAPPA T, Ahmadi S, Marqusee E, Johnson HL, et al
    Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAF(V600E)-driven papillary thyroid cancer patients.
    Clin Cancer Res. 2021 Jun 4. pii: 1078-0432.CCR-21-0874.
    PubMed     Abstract available

  69. OPENSHAW MR, Pinato DJ, Valeri N
    Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer.
    Clin Cancer Res. 2021;27:2964-2966.
    PubMed     Abstract available

  70. HEGDE A, Jayaprakash P, Couillault CA, Piha-Paul S, et al
    A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
    Clin Cancer Res. 2021;27:3050-3060.
    PubMed     Abstract available

  71. PENG Z, Wei J, Wang F, Ying J, et al
    Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2021;27:3069-3078.
    PubMed     Abstract available

  72. CORSO S, Pietrantonio F, Apicella M, Migliore C, et al
    Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas.
    Clin Cancer Res. 2021;27:3126-3140.
    PubMed     Abstract available

    May 2021
  73. LEE RH, Kang H, Yom SS, Smogorzewska A, et al
    Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-1259.
    PubMed     Abstract available

  74. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
    FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
    PubMed     Abstract available

    April 2021
  75. LI D, Chi Y, Chen X, Ge MH, et al
    Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
    Clin Cancer Res. 2021 Apr 8. pii: 1078-0432.CCR-20-2950.
    PubMed     Abstract available

    A PERFECT biomarker-focused study of neoadjuvant IO for esophagogastric cancer.
    Clin Cancer Res. 2021 Apr 6. pii: 1078-0432.CCR-21-0324.
    PubMed     Abstract available

  77. WAINBERG ZA, Fuchs CS, Tabernero J, Shitara K, et al
    Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score >/=10.
    Clin Cancer Res. 2021;27:1923-1931.
    PubMed     Abstract available

    March 2021
  78. LEI M, Siemers NO, Pandya D, Chang H, et al
    Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab{plus minus}Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
    Clin Cancer Res. 2021 Mar 29. pii: 1078-0432.CCR-20-2790.
    PubMed     Abstract available

  79. ZHAO M, Scott S, Evans KW, Yuca E, et al
    Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
    Clin Cancer Res. 2021;27:1681-1694.
    PubMed     Abstract available

    February 2021
  80. KLEIN S, Quaas A, Quantius J, Loser H, et al
    Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains.
    Clin Cancer Res. 2021;27:1131-1138.
    PubMed     Abstract available

  81. FERRAROTTO R, Mitani Y, McGrail DJ, Li K, et al
    Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
    Clin Cancer Res. 2021;27:852-864.
    PubMed     Abstract available

    January 2021
  82. WATERMANN C, Pasternack H, Idel C, Ribbat-Idel J, et al
    Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion.
    Clin Cancer Res. 2021;27:632-644.
    PubMed     Abstract available

    December 2020
  83. THAKUR S, Daley B, Millo C, Cochran C, et al
    (177)Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.
    Clin Cancer Res. 2020 Dec 22. pii: 1078-0432.CCR-20-3453.
    PubMed     Abstract available

    November 2020
  84. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
    Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
    PubMed     Abstract available

    September 2020
  85. GRAY KD, McCloskey JE, Vedvyas Y, Kalloo OR, et al
    PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer.
    Clin Cancer Res. 2020 Sep 4. pii: 1078-0432.CCR-20-1523.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.